Compare ASML Holding NV (ASML) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs Crispr Therapeutics AG — how do they compare? ASML Holding NV trades at $1,828.9 (market cap $689.17B), while Crispr Therapeutics AG trades at $54.7 (market cap $5.23B). The key difference: ASML Holding NV is far larger — about 131.8× Crispr Therapeutics AG's market cap, and ASML Holding NV pays a 0.5% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ASML | CRSP | |
|---|---|---|
Market Cap | $689.17B | $5.23B |
Sector | Technology | Health |
52-Week High | $1.99K | $76.78 |
52-Week Low | $725.85 | $44.34 |
Enterprise Value | $682.70B | $3.65B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,733.48, down 0.43% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a 29.41% net income margin and robust revenue growth to $32.67B in 2025. Recent earnings beats in Q1 and Q2 2026, coupled with a consensus price target of $2,390, highlight positive momentum, though high valuation ratios like a P/E of 61.28 pose risks.
Outlook remains favorable due to AI-driven semiconductor demand, but investors face risks from geopolitical tensions with China and stretched valuations. Analyst consensus is strongly bullish with 57% buy ratings, supporting potential upside, though monitoring competitive threats and earnings consistency is crucial for sustained growth.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
